162. 類天疱瘡(後天性表皮水疱症を含む。)
[臨床試験数:70,薬物数:117(DrugBank:46),標的遺伝子数:30,標的パスウェイ数:128

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04612790
(ClinicalTrials.gov)
November 3, 202012/10/2020A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)Bullous PemphigoidBiological: Benralizumab;Biological: PlaceboAstraZenecaNULLNot yet recruiting18 Years130 YearsAll120Phase 3United States;Bulgaria;Germany;Italy